Key Insights• China Chinese bioceramics market operates within a healthcare environment defined by the world's largest patient population, a national imperative to reduce import dependence, and a transformative bulk procurement policy that has fundamentally altered the economics of joint replacement. Osteoarthritis is a major public health challenge in China, with the National Health Commission reporting a total prevalence of 15%, representing over 100 million patients with some estimates suggesting the figure exceeds 140 million. Among those aged 40 and above, the prevalence reaches 46.3%, and among those aged 60 and above, it exceeds 50%, underscoring the substantial and growing clinical burden. In 2024, China performed approximately 2.44 million joint replacement procedures, representing a 22% year-on-year increase, with projections for 2025 reaching 2.8 to 3.0 million procedures. The proportion of patients aged 60 and older undergoing total knee and hip arthroplasty has shown a significant increase, reflecting the accelerating demographic transition in China.• China’s healthcare delivery model for Bioceramics devices is distinguished by the Hospital Quality Monitoring System (HQMS), a mandatory national inpatient database administered by the National Health Commission. Since 2013, tertiary hospitals across all 31 provincial-level administrative regions in mainland China have been required to upload inpatient discharge records to the HQMS.

This database has enabled nationwide studies on total joint arthroplasty trends, providing critical insights into patient demographics and procedural volumes. However, China has not yet established a comprehensive national arthroplasty registry comparable to those in Sweden, England, or Australia, with researchers noting that "China has not yet built a decent artificial joint replacement registration and follow-up system on national scales." This gap in implant surveillance infrastructure represents both a challenge and an opportunity for systematic post-market monitoring of Bioceramics devices. In the dental sector, China's dental implant market is experiencing rapid growth, driven by rising disposable incomes, increasing awareness of oral health, and the expanding middle class.• Regulatory oversight for medical devices in China is administered by the National Medical Products Administration (NMPA). The NMPA has issued specific guidance for calcium/phosphorus/silicon bone filling materials, including synthetic calcium phosphate bioceramics, calcium-silicon bioactive glasses and glass-ceramics, and calcium phosphate bone cements. These products are indicated for filling bone defects caused by orthopedic trauma and surgery in the limbs and spine that do not affect bone structural stability. The NMPA has also published guidance on the technical review of additively manufactured Bioceramics bone filling materials.

In March 2025, the NMPA approved 308 medical device products, including 248 domestic Class III medical devices, reflecting the robust domestic innovation pipeline. The Chinese bioceramics market is characterized by a dynamic interplay between domestic manufacturers and international suppliers, with companies such as Beijing Arthrone Technology, TrendTec New Materials, and Shanghai Biolu Biomaterials emerging as significant domestic players in Bioceramics orthopedic and dental applications.Market Outlook• According to the research report, "China Bioceramics Market Outlook, 2031," published by Actual Market Research, the China Bioceramics Market is anticipated to add to more than 300 Million by 2026-31.• A defining characteristic of China's bioceramics market is the transformative impact of the National Healthcare Security Administration's bulk procurement program for artificial joints. The procedure that replaces degenerated joints with artificial ones could previously cost as much as 50,000 yuan ($6,800). Today, thanks to the bulk procurement program led by the National Healthcare Security Administration, the price of such surgeries has significantly dropped. China has rolled out four rounds of bulk-buy programs targeting high-value medical consumables, including artificial joints, intraocular lenses, and orthopedic supplies. The National Organizing Joint Procurement Office for High-Value Medical Consumables has continued to implement and expand the centralized procurement framework for artificial joints, with ongoing processes for successor procurement and supplementary product additions.

This policy has dramatically increased patient access to joint replacement procedures, directly driving demand for Bioceramics components. Simultaneously, the program has intensified price competition among implant manufacturers, creating both opportunities for domestic Bioceramics producers offering cost-competitive solutions and challenges for premium imported ceramic components.• The market also reflects China's strategic national imperative to achieve "self-reliance" in high-end medical device manufacturing, moving from "import dependence" to "independent control." The Ministry of Industry and Information Technology and the NMPA have jointly launched the "Bio-Medical Materials Innovation Task, Open Competition" initiative, designating leading domestic manufacturers to spearhead critical projects. One such project focuses on the "Fifth Generation Ceramic Hip Joint Silicon Nitride Ceramic Joint," targeting breakthroughs in biocompatibility, wear resistance, and impact strength to extend implant longevity. Another project, led by the PLA General Hospital Fourth Medical Center in collaboration with domestic materials and medical device companies, has established a complete closed-loop system from upstream material supply to midstream device R&D to downstream clinical trial improvement, aiming to break through China's technical barriers in ceramic hip joint prosthesis manufacturing. The development of a complete domestic production chain for bioinert ceramics from raw material synthesis to finished endoprostheses represents a critical strategic objective for reducing import dependence and strengthening China's position in the global bioceramics market Market DynamicsDriver: Growing Demand from an Aging Population and Expanding Healthcare AccessChina's bioceramics market is driven by a rapidly aging population and the world's largest osteoarthritis patient base. More than 100 million people are affected by osteoarthritis, fueling strong demand for orthopedic implants and bone repair materials.

Rising healthcare coverage, higher disposable incomes, and improved affordability through the National Healthcare Security Administration's bulk procurement program have significantly increased joint replacement procedures. The growing elderly population and expanding access to orthopedic and dental care continue to support demand for Bioceramics implants, making China one of the fastest-growing markets for orthopedic biomaterials.Challenge: Dependence on Imported High-Performance Ceramic MaterialsA major challenge for China's bioceramics market is its continued reliance on imported medical-grade ceramic raw materials, particularly high-purity alumina and zirconia powders. Although domestic manufacturers are expanding production of Bioceramics components, upstream material supply remains limited, exposing the market to supply chain disruptions and geopolitical risks. Additionally, the absence of a comprehensive national joint replacement registry restricts long-term implant performance monitoring and post-market surveillance. Strengthening domestic raw material production and improving implant tracking systems remain critical priorities for supporting sustainable industry growth.Trend: Expansion of Domestic Bioceramics Innovation and ManufacturingChina is accelerating domestic Bioceramics innovation to reduce import dependence and strengthen its medical device industry. Government-supported initiatives are encouraging research, advanced material development, and local production of orthopedic and dental bioceramics.

Domestic manufacturers are expanding capabilities in zirconia implants, calcium phosphate bone substitutes, and next-generation ceramic joint components while adopting advanced manufacturing technologies such as additive manufacturing and precision processing. These investments are strengthening the domestic supply chain, improving product quality, and positioning China as an increasingly competitive global producer of advanced Bioceramics materials. Policies NMPA Medical Device Registration and Classification: All implantable Bioceramics medical devices must obtain registration with the National Medical Products Administration (NMPA) before they can be marketed and distributed in China. Devices are classified based on risk, with implantable devices typically classified as Class III, requiring the most rigorous review. The NMPA has issued specific guidance for calcium/phosphorus/silicon bone filling materials, including synthetic calcium phosphate bioceramics, calcium-silicon bioactive glasses and glass-ceramics, and calcium phosphate bone cements. Additionally, the NMPA has published guidance on the technical review of additively manufactured Bioceramics bone filling materials. In March 2025, the NMPA approved 308 medical device products, including 248 domestic Class III medical devices.National Healthcare Security Administration Bulk Procurement for Artificial Joints The National Healthcare Security Administration has implemented a centralized bulk procurement program for high-value medical consumables, including artificial joints, intraocular lenses, and orthopedic supplies.

The program has significantly reduced the cost of joint replacement procedures, which previously could cost as much as 50,000 yuan ($6,800). The National Organizing Joint Procurement Office for High-Value Medical Consumables continues to implement and expand the centralized procurement framework. HQMS National Inpatient Database and Implant Surveillance: The Hospital Quality Monitoring System (HQMS), administered by the National Health Commission, is a mandatory national inpatient database. Since 2013, tertiary hospitals across all 31 provincial-level administrative regions have been required to upload inpatient discharge records. The HQMS has enabled nationwide studies on total joint arthroplasty trends. However, China has not yet established a comprehensive national arthroplasty registry, with experts recommending that "China quicken the establishment of a national arthroplasty registry, improve the system for regulation of whole lifecycle of medical devices and enhance the ability to monitor the safety of implants."Bio-Medical Materials Innovation Task, Open Competition Initiative: The Ministry of Industry and Information Technology and the NMPA have jointly launched the "Bio-Medical Materials Innovation Task, Open Competition" initiative, designating leading domestic manufacturers to spearhead critical projects. This initiative aims to accelerate breakthroughs in critical medical materials and reduce import dependence in high-end medical device manufacturing.Segment AnalysisChina Bioceramics Market By Type• Bioinert Ceramics represents the largest product category in China, driven by the massive and rapidly growing volume of joint replacement procedures.

China performed approximately 2.44 million joint replacement procedures in 2024, a 22% year-on-year increase, with projections for 2025 reaching 2.8 to 3.0 million procedures. Bioinert ceramics including alumina and zirconia femoral heads maintain their physical integrity in the body and are ideal for load-bearing applications. Zirconia ceramic femoral heads, such as those produced by Beijing Arthrone Technology and approved by NMPA in early 2025, are critical components in hip replacements. The growing proportion of patients aged 60 and older undergoing total knee and hip arthroplasty drives demand for durable bioinert ceramic components. In dental applications, bioinert zirconia is increasingly preferred for implants and restorations, supported by the rapid growth of China's dental implant market and the expansion of domestic manufacturing capabilities.• Bioactive Ceramics maintains an important position in China, particularly in applications requiring bone bonding, including hydroxyapatite coatings, bioactive glass, and bone graft substitutes. The NMPA has issued specific guidance for calcium/phosphorus/silicon bone filling materials, including synthetic calcium phosphate bioceramics, calcium-silicon bioactive glasses and glass-ceramics, and calcium phosphate bone cements.

These products are indicated for filling bone defects caused by orthopedic trauma and surgery in the limbs and spine. In January 2026, Zhenghai Biotechnology received NMPA registration for its calcium-silicon Bioceramics oral bone repair material, a Class III medical device manufactured using three-dimensional printing and high-temperature sintering. Shanghai Biolu Biomaterials specializes in β-tricalcium phosphate Bioceramics (Biolu artificial bone) medical device R&D and production.• Bioresorbable Ceramics represents the fastest-growing type segment in China, driven by increasing demand for temporary implants, bone void fillers, and drug delivery systems. These materials gradually dissolve and are replaced by natural bone, making them particularly valuable in applications where permanent implants are unnecessary. The NMPA's guidance on calcium/phosphorus/silicon bone filling materials and additively manufactured Bioceramics bone filling materials reflects the growing regulatory focus on this segment. In June 2026, the NMPA issued a Class III medical device registration for Dabo Medical's complex-phase calcium phosphate Bioceramics filling product, further expanding the domestic bioresorbable product portfolio.China Bioceramics Market By Material• Zirconia represents a leading material category in China, driven by the country's rapidly growing joint replacement and dental implant markets.

Beijing Arthrone Technology received NMPA approval for its innovative "Zirconia Ceramic Femoral Head" in early 2025, a component of a hip joint prosthesis made from zirconia ceramic material. Zirconia's superior fracture toughness and aesthetic translucency make it the preferred material for dental implants and restorations. The number of zirconia ceramic femoral head approvals and domestic manufacturing capabilities continues to expand, reflecting the strategic importance of reducing import dependence in this critical material category.• Alumina maintains an important position in Chinese orthopedics, with alumina ceramic heads widely used in hip replacements. While pure alumina is gradually being replaced by Zirconia-Toughened Alumina (ZTA) in premium applications, alumina remains a cost-effective option for many procedures. The domestic production of high-purity alumina powder for medical applications remains an area of strategic focus, as China currently depends on imports for high-performance ceramic raw materials.• Calcium Phosphate is a critical material category encompassing hydroxyapatite and β-tricalcium phosphate for bone graft substitutes and implant coatings. Shanghai Biolu Biomaterials specializes in β-tricalcium phosphate Bioceramics (Biolu artificial bone) medical device R&D and production, holding Class III medical device operating licenses.

In June 2026, the NMPA issued a Class III medical device registration for Dabo Medical's complex-phase calcium phosphate Bioceramics filling product. The NMPA's guidance on calcium/phosphorus/silicon bone filling materials reflects the growing clinical importance of calcium phosphate-based products.• Calcium Sulfate holds a niche position in the Chinese market, primarily used as a synthetic bone void filler and antibiotic-eluting carrier for the treatment of osteomyelitis and infected surgical sites. The market for calcium sulfate products is supported by the NMPA's regulatory framework for bone filling materials.• Others (Carbon-based Ceramic, Bioactive Glass) includes carbon-based ceramics for cardiovascular applications, bioactive glass for bone regeneration, and emerging Bioceramics materials. Zhenghai Biotechnology's calcium-silicon Bioceramics oral bone repair material is manufactured using three-dimensional printing and high-temperature sintering, achieving a porous structure comparable to autologous bone. The NMPA's guidance on calcium/phosphorus/silicon bone filling materials includes calcium-silicon bioactive glasses and glass-ceramics, reflecting the regulatory recognition of these emerging materials.China Bioceramics Market By Application• Orthopedics represents the largest application segment in China, driven by the massive and rapidly growing burden of osteoarthritis. The National Health Commission reports that China's total osteoarthritis prevalence is 15%, representing over 100 million patients.

In 2024, China performed approximately 2.44 million joint replacement procedures, a 22% year-on-year increase. Projections for 2025 reach 2.8 to 3.0 million procedures. The proportion of patients aged 60 and older undergoing total knee and hip arthroplasty has shown a significant increase. Orthopedic applications include ceramic femoral heads, ceramic knee components, calcium phosphate bone grafts, and hydroxyapatite coatings. The National Healthcare Security Administration's bulk procurement program has dramatically increased patient access to joint replacement procedures, directly driving demand for Bioceramics components. Beijing Arthrone Technology's zirconia ceramic femoral head and TrendTec New Materials' hip joint ceramic materials represent domestic manufacturing capabilities in this segment.• Dental represents a rapidly growing application segment in China, driven by rising disposable incomes, increasing awareness of oral health, and the expanding middle class.

In January 2026, Zhenghai Biotechnology received NMPA registration for its calcium-silicon Bioceramics oral bone repair material, a Class III medical device. Zirconia is the preferred material for dental implants and restorations. The number of dental implant procedures in China continues to grow rapidly, supported by the expansion of private dental clinics and the increasing availability of domestic Bioceramics products.• Biomedical & Others encompasses tissue engineering scaffolds, drug delivery systems, cardiovascular applications, surgical instruments, and wound healing products. Chinese research institutions, including Wuhan University of Technology's Biomaterials and Engineering Research Center, continue to investigate novel Bioceramics materials. Wuhan Huaxia Biomaterials Engineering Co., Ltd. has obtained administrative licenses for porous Bioceramics bone filling materials and orthopedic repair materials. The Ministry of Industry and Information Technology and NMPA's "Bio-Medical Materials Innovation Task, Open Competition" initiative is accelerating innovation in emerging Bioceramics applications.Major Bioceramics Manufacturers Operating in China• Beijing Arthrone Technology Co., Ltd. received NMPA approval for its innovative "Zirconia Ceramic Femoral Head" in early 2025, a hip joint prosthesis component made from zirconia ceramic material.

Anso Technology is driving the transformation of orthopedic implants from "import dependence" to "independent control" through material innovation, precision manufacturing, and clinically oriented design.• TrendTec New Materials, founded in 2020, specializes in the research, development, and sales of high-end implant and interventional medical devices, particularly hip joint ceramic materials, with femoral heads and liners formally registered with China's NMPA.• Dabo Medical received NMPA registration for its complex-phase calcium phosphate Bioceramics filling product in June 2026. The company was selected as the lead unit for two "Bio-Medical Materials Innovation Task, Open Competition" projects: "Zirconium-Niobium Alloy Key Technology and Industrialization" and "High-Toughness Ultra-Wear-Resistant Coating Technology Development and Application."• Shanghai Biolu Biomaterials Co., Ltd. specializes in β-tricalcium phosphate Bioceramics (Biolu artificial bone) medical device R&D and production, holding Class III medical device operating licenses.• Zhenghai Biotechnology received NMPA registration for its calcium-silicon Bioceramics oral bone repair material in January 2026.• Wuhan Huaxia Biomaterials Engineering Co., Ltd., with technical support from Wuhan University of Technology's Biomaterials and Engineering Research Center, has obtained administrative licenses for porous Bioceramics bone filling materials and orthopedic repair materials.• International players with significant presence include Zimmer Biomet, Stryker, DePuy Synthes, Smith & Nephew, CeramTec, Straumann, and Dentsply Sirona. The market is also supported by distributors and procurement organizations that provide commercialization, maintenance, and supply chain support.China Bioceramics Procedure Economics• Bioceramics implantation in China operates under the National Healthcare Security Administration's bulk procurement framework for artificial joints. The procedure that replaces degenerated joints with artificial ones could previously cost as much as 50,000 yuan ($6,800). Today, thanks to the bulk procurement program, the price of such surgeries has significantly dropped. The National Organizing Joint Procurement Office for High-Value Medical Consumables continues to implement and expand the centralized procurement framework.• China has rolled out four rounds of bulk-buy programs targeting high-value medical consumables, including artificial joints, intraocular lenses, and orthopedic supplies.

Knee replacement procedures account for approximately 43% of joint replacement surgeries in the centralized procurement program, while hip replacement procedures account for approximately 57%.• For hip replacements, the choice of bearing surface material is critical, with the primary options being ceramic-on-ceramic, ceramic-on-polyethylene, and metal-on-polyethylene. These options differ in their mechanical and biological properties.• In the dental sector, the cost of dental implants varies significantly depending on the material, manufacturer, and clinic location. The increasing availability of domestically manufactured zirconia implants and Bioceramics bone repair materials is expected to make dental implant procedures more affordable and accessible to a broader patient population.• Long-term costs include device monitoring, imaging surveillance, and revision procedures. Revision surgeries account for approximately 10% of total joint replacement procedures, with revision demand expected to increase as the number of primary joint replacements grows and implant lifecycles reach their endpoint.China Bioceramics Market By End User• Hospitals and Surgical Centers dominate Bioceramics utilization in China. The HQMS national inpatient database, administered by the National Health Commission, collects data from tertiary hospitals across all 31 provincial-level administrative regions. In 2024, China performed approximately 2.44 million joint replacement procedures, with projections for 2025 reaching 2.8 to 3.0 million procedures.

Beijing region's joint replacement volume has reached approximately 26,000 cases, a significant increase from approximately 16,000 cases in 2019.• Dental Clinics and Laboratories represent a rapidly growing end-user category, driven by rising disposable incomes, increasing awareness of oral health, and the expanding middle class. Domestic manufacturing of zirconia dental implants and Bioceramics bone repair materials, such as Zhenghai Biotechnology's calcium-silicon Bioceramics oral bone repair material, is expanding access to dental implant procedures.• Others includes medical device manufacturers (OEMs), academic research institutions, and biotechnology companies. Chinese research institutions, including Wuhan University of Technology's Biomaterials and Engineering Research Center, continue to advance Bioceramics research and development. The Ministry of Industry and Information Technology and NMPA's "Bio-Medical Materials Innovation Task, Open Competition" initiative is accelerating domestic innovation in Bioceramics materials and devices.China Bioceramics Market By Form• Liquid (Injectable) & Others represents a growing form segment in China, driven by the increasing adoption of ready-to-use formulations including injectable bone cements, premixed calcium phosphate pastes, flowable bone graft putties, and pre-sintered dental blocks for CAD/CAM milling. The NMPA's guidance on calcium/phosphorus/silicon bone filling materials includes calcium phosphate bone cements, reflecting the regulatory recognition of injectable formulations. The adoption of digital dentistry technologies, including CAD/CAM systems and three-dimensional printing, supports demand for pre-sintered zirconia blocks and other ready-to-use forms.

Zhenghai Biotechnology's calcium-silicon Bioceramics oral bone repair material is manufactured using three-dimensional printing, demonstrating the growing integration of additive manufacturing in Bioceramics production.• Powder maintains an important position as raw material feedstock for OEM manufacturing, plasma-spray coating of metallic implants, and on-site mixing for bone graft applications. Powder forms are primarily purchased by medical device manufacturers and hospitals for custom preparation. China's import trends for ceramic biomaterials reflect ongoing demand for high-purity ceramic powders, with the domestic production of these materials being a strategic priority to reduce import dependence. The Ministry of Industry and Information Technology and NMPA's "Bio-Medical Materials Innovation Task, Open Competition" initiative is accelerating domestic powder production capabilities.Market Outlook by Healthcare Spending and Infrastructure• China's bioceramics market growth is linked to the country's position as the world's largest and fastest-growing joint replacement market. China performed approximately 2.44 million joint replacement procedures in 2024, a 22% year-on-year increase, with projections for 2025 reaching 2.8 to 3.0 million procedures. The National Healthcare Security Administration's bulk procurement program has dramatically increased patient access to joint replacement procedures, directly driving demand for Bioceramics components.• The HQMS national inpatient database provides critical data for analyzing clinical outcomes and healthcare utilization, though the absence of a comprehensive national joint registry limits systematic implant surveillance.

Experts recommend that "China quicken the establishment of a national arthroplasty registry, improve the system for regulation of whole lifecycle of medical devices and enhance the ability to monitor the safety of implants."• The future growth opportunity for bioceramics in China depends on continued investment in domestic manufacturing capabilities, the establishment of a comprehensive national joint registry, the expansion of joint replacement services to underserved regions, and the successful implementation of the "Bio-Medical Materials Innovation Task, Open Competition" initiative. The Ministry of Industry and Information Technology and NMPA's strategic focus on reducing import dependence in high-end medical device manufacturing positions China as a rapidly emerging global player in bioceramics innovation and production.• Professional organizations including the Chinese Orthopaedic Association (COA) continue to advance the field through clinical research, guideline development, and professional education. The "Clinical Diagnosis and Treatment Guidelines for Artificial Joint Replacement in China (2025 Edition)" provides comprehensive guidance on indications, contraindications, preoperative evaluation, and surgical techniques. The National Health Commission continues to conduct epidemiological surveillance of osteoarthritis through national health surveys, informing healthcare planning and resource allocation for joint replacement services.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Bioceramics Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Type• Bioinert Ceramics• Bioactive Ceramics• Bioresorbable CeramicsBy Material• Alumina• Zirconia• Calcium Phosphate• Calcium Sulfate• Others (carbon-based ceramic, Bio activated Glass)By Application• Orthopedics• Dental• Biomedical & othersBy End User• Hospitals and Surgical Centers• Dental Clinics and Laboratories• OthersBy Form• Powder• Liquid (Injectable) & Others.